VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
1.030
-0.040 (-3.74%)
At close: Jun 26, 2026, 4:00 PM EDT
1.090
+0.060 (5.83%)
After-hours: Jun 26, 2026, 7:30 PM EDT
VivoSim Labs Employees
VivoSim Labs had 13 employees as of March 31, 2025. The number of employees decreased by 7 or -35.00% compared to the previous year.
Employees
13
Change (1Y)
-7
Growth (1Y)
-35.00%
Revenue / Employee
$10,143
Profits / Employee
-$87,643
Market Cap
2.98M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Calidi Biotherapeutics | 29 |
| Virax Biolabs Group | 19 |
| Azitra | 13 |
| Decoy Therapeutics | 11 |
| CDT Equity | 4 |
| GRI Bio | 4 |
| SciSparc | 3 |
| Oragenics | 3 |
VIVS News
- 2 months ago - VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing - GlobeNewsWire
- 3 months ago - VivoSim Announces Pricing of up to a $4 Million Public Offering - GlobeNewsWire
- 3 months ago - VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs - GlobeNewsWire
- 4 months ago - VivoSim appoints Arumugham Raghunathan as VP, global sales - TheFly
- 4 months ago - VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales - GlobeNewsWire
- 4 months ago - VivoSim to debut antibody drug conjugate data at SOT meeting - TheFly
- 4 months ago - VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego - GlobeNewsWire
- 5 months ago - VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China - GlobeNewsWire